Author: bobby
Modern Strategies Transforming Drug Discovery Research
Modern Strategies Transforming Drug Discovery Research Drug discovery research is evolving fast, driven by technological advances and a shift toward more predictive, patient-centric approaches. Teams that combine biology, chemistry, engineering, and computational science are shortening timelines and improving the chance that promising molecules become safe, effective medicines. Structure-led design and high-resolution biologyHigh-resolution structural techniques such…
Read More
Biotech Startups Playbook: From Discovery to Scalable, Market-Ready Products
Biotech startups are reshaping medicine, agriculture, and materials by turning breakthrough science into tangible products. Success requires more than great science: founders must navigate funding cycles, regulatory pathways, manufacturing scale-up, and talent acquisition while convincing partners and payers of real-world value. Here’s a pragmatic playbook for startups that want to move from discovery to durable…
Read More
Practical guide to regulatory affairs for digital health products
Practical guide to regulatory affairs for digital health products Digital health continues to reshape care delivery, and regulatory affairs teams must adapt quickly. Software as a Medical Device (SaMD), mobile medical apps, and connected combination products create new challenges around classification, clinical evidence, cybersecurity, and post-market obligations. A proactive regulatory strategy reduces risk, accelerates time…
Read More
How to Build Compliant Post‑Market Surveillance & Real‑World Evidence Programs: Practical Guidance for Regulatory Affairs
Post-Market Surveillance and Real-World Evidence: Practical Guidance for Regulatory Affairs Regulatory affairs teams face growing expectations to demonstrate product safety and effectiveness across the lifecycle. Post-market surveillance (PMS) and real-world evidence (RWE) are now core tools for meeting those expectations, supporting regulatory submissions, safety signals, label updates, and market access. The following practical guidance helps…
Read More
Personalized Medicine: How Genomics and Digital Health Tailor Your Care
Personalized Medicine: Tailoring Care to the Individual Personalized medicine — often called precision medicine — shifts healthcare from a one-size-fits-all model to treatments and prevention strategies tailored to an individual’s biology, lifestyle, and environment. By combining genomic insights, biomarker profiling, and digital health data, clinicians can choose therapies that are more likely to work and…
Read More
Precision Drug Discovery: Integrating Structural Biology, Patient-Derived Models, and Chemical Proteomics to Speed Target Validation
Modern drug discovery is shifting from one-size-fits-all screening to precision-enabled strategies that connect molecular insight with patient biology. Teams that combine structural biology, patient-derived models, chemical proteomics, and advanced computational methods are moving candidates from target validation to clinic with greater confidence and speed. What’s driving progress– High-resolution structural biology: Cryo-electron microscopy and improved X-ray…
Read More
Why Leen Kawas Believes Founders Should Stay Close to the Science
Biotech startups often face a familiar tension: the need to scale as a business while still advancing complex scientific programs. For many founders, this creates a pull away from the laboratory and toward investor presentations, board meetings, and market strategy. Leen Kawas, co-founder and managing general partner of Propel Bio Partners, argues that the best…
Read More
Primary title:
Biotech startups are rewriting what’s possible in medicine, agriculture, and sustainable materials. Fueled by advances in gene editing, cell therapies, synthetic biology, and computational drug discovery, these companies turn complex science into commercial products. That opportunity comes with distinct hurdles: intensive capital needs, long development timelines, regulatory complexity, and manufacturing scale-up. Navigating this landscape well…
Read More
Modernizing Pharmaceutical Manufacturing: Efficiency, Quality & Resilience with Continuous Processing and Pharma 4.0
Pharmaceutical manufacturing is navigating a period of rapid modernization as manufacturers balance demands for higher efficiency, tighter quality control, and greater supply chain resilience. Advances in digital technologies, process design, and materials are reshaping how medicines are developed and produced, with practical strategies available for companies of all sizes. Key trends driving change– Continuous manufacturing:…
Read More
Decentralized Clinical Trials: How Patient-Centric, Digital Designs Accelerate Development and Boost Diversity
Clinical trials are evolving from rigid, site-centered operations into flexible, patient-focused programs that balance speed, quality, and inclusivity. Sponsors, CROs, and research sites that adopt modern trial designs and digital tools can reduce timelines, improve data quality, and broaden participant diversity — all while meeting tighter regulatory expectations. Key trends reshaping clinical trial design –…
Read More